nach oben

Erschienen in:

01.06.2013 | INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTION EDITOR)

Autoantibodies in Polymyositis and Dermatomyositis

verfasst von: Anna Ghirardello, Nicola Bassi, Lavinia Palma, Elisabetta Borella, Marta Domeneghetti, Leonardo Punzi, Andrea Doria

Erschienen in: Current Rheumatology Reports | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory myopathies are a group of acquired diseases, characterized by immunoflogistic processes primarily involving the skeletal muscle. According to recent classification criteria, four major diseases have been identified: polymyositis (PM), dermatomyositis (DM), sporadic inclusion body myositis (IBM), and necrotizing autoimmune myositis (NAM). Autoantibodies can be found in the sera of most patients with myositis. Myositis-specific autoantibodies (MSAs) are markers of very specific disease entities within the spectrum of myositis, and target proteins involved in key processes of protein synthesis. Myositis autoantigens comprise the well-defined aminoacyl-tRNA synthetases, the Mi-2 helicase/histone deacetylase protein complex, and the signal recognition particle (SRP) ribonucleoprotein, together with novel targets such as TIF1-γ, MDA5, NXP2, SAE, and HMGCR. Recent studies suggest that autoantigens drive a B cell antigen-specific immune response in muscles. Interestingly, an increased expression of Jo-1 and Mi-2 in regenerating fibers in muscle biopsies from PM and DM patients compared to normal was demonstrated. Myositis autoantigen up-regulation was observed in neoplastic tissues, thus representing a potential link between cancer and autoimmunity in myositis. Non-immunological mechanisms seem to participate to the pathogenesis of inflammatory myopathies; induction of endoplasmic reticulum stress response in response to abnormal muscle regeneration and inflammation has recently been reported in patients with myositis. This review article provides an update of new emerging insights about the clinical and pathophysiologic role of principal autoantibodies in myositis.

Bohan A, Peter JB. Polymyositis and dermatomyositis (first part). N Engl J Med. 1975;292:344–7.PubMedCrossRef

Bohan A, Peter JB. Polymyositis and dermatomyositis (second part). N Engl J Med. 1975;292:403–7.PubMedCrossRef

Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82.PubMedCrossRef

Mathiesen PR, Zak M, Heilin T, Nielsen SM. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin Exp Rheumatol. 2010;28:782–9.PubMed

• Dalakas MC. Review: an update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol. 2011;37:226–42. In this review article, distinct histopathological features and pathological mechanisms of the main types of inflammatory and autoimmune myopathies are described in detail.PubMedCrossRef

Hengstman GJD, Brouwer R, Vree Egberts WTM, Jougen PJH, Seelig HP, Van Venrooij WJ, et al. Clinical and serological characteristics of 125 Dutch myositis patients; myositis specific autoantibodies aid in the differential diagnosis of idiopathic inflammatory myopathies. J Neurol. 2002;249:69–75.PubMedCrossRef

Targoff IN. Autoantibodies and their significance in myositis. Curr Rheumatol Rep. 2008;10:333–40.PubMedCrossRef

Vincze M, Molnar PA, Tumpek J, Szollosi L, Gyetvai A, Kapitani A, et al. An unusual association: anti-Jo-1 and anti-SRP antibodies in the serum of a patient with polymyositis. Clin Rheumatol. 2010;29:811–4.

Sugie K, Tonomura Y, Ueno S. Characterization of dermatomyositis with coexistence of anti-Jo-1 and anti-SRP antibodies. Int Med. 2011;51:799–802.CrossRef

10.

Nakajima A, Yoshino K, Soejima M, Kawaguchi Y, Satoh T, Kuwana M, et al. High frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis. Rheumatol Int. 2012;32:2057–61.PubMedCrossRef

11.

Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A. Anti-Jo-1 antibodies. Autoimmunity. 2005;38:73–8.PubMedCrossRef

12.

Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, et al. Anti-Mi-2 autoantibodies. Autoimmunity. 2005;38:79–83.PubMedCrossRef

13.

Hengstman GJD, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2β antigen. Ann Rheum Dis. 2006;65:242–5.

14.

Brouwer R, Hengstmam GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, et al. Autoantibodies profiles in the sera of European patients with myositis. Ann Rheum Dis. 2001;60:116–23.PubMedCrossRef

15.

Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006;65:1635–8.PubMedCrossRef

16.

Ghirardello A, Zampieri S, Tarricone E, Iaccarino L, Gorza L, Doria A. Cutting edge issues in polymyositis. Clin Rev Allergy Immunol. 2011;41:179–89.PubMedCrossRef

17.

• Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25–34. This retrospective study provides clues to the mucocutaneous and systemic features specifically associated with anti-MDA5 antibodies in adult patients with DM.PubMedCrossRef

18.

Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. 2011;13:R209.CrossRef

19.

•• Mammen AL, Chung T, Christopher- Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63:713–21. The target antigen of anti-200/100kDa antibodies was identified as the 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Moreover, it was shown that statin exposure induces HMGCR overexpression in muscle fibers in vitro, and HMGCR is expressed at high levels in regenerating muscle fibers from anti-HMGCR-positive patients.PubMedCrossRef

20.

Hengstman GJD, van Brenk L, Vree Egberts WTM, Van der Kooij EL, Borm GF, Padberg GWAM, et al. High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. J Neurol. 2005;252:534–7.PubMedCrossRef

21.

Suzuki S, Satoh T, Sato S, Otomo M, Hirayama Y, Sato H, et al. Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology (Oxford). 2008;47:1539–42.CrossRef

22.

Gunawardena H, Betteridge ZE, McHugh NJ. Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol. 2008;20:675–80.PubMedCrossRef

23.

Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77:1019–38.PubMedCrossRef

24.

• Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, et al. Overlap connective tissue disease syndromes. Autoimmun Rev. 2012;3:363–73. An interesting overview of the diagnosis, classification, and current treatment approach of overlap syndromes is presented.

25.

Christopher-Stine L, Robinson DR, Wu CC, Mark EJ. Case 37–2012: a 21-year-old man with fever, arthralgias, and pulmonary infiltrates. N Eng J Med. 2012;367:2134–46.CrossRef

26.

Ghirardello A, Zampieri S, Tarricone E, Iaccarino L, Bendo R, Briani C, et al. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity. 2006;39:217–21.PubMedCrossRef

27.

Harvier B, Wallaert B, Machulla E, Adoue D, Lauque D, Audrain M, et al. Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford). 2010;49:972–6.CrossRef

28.

Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol. 2010;22:633–8.PubMedCrossRef

29.

• Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, Dankó K, Vencovsky J, Fisher B, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore). 2012;91:206–11. This retrospective multicenter study of a large European myositis cohort confirmed the association of anti-PL-7 antibodies with the major clinical features of antisynthetase syndrome. In addition, pericardial effusion was found associated with anti-PL-7 antibody. This novel finding needs to be further studied.CrossRef

30.

•• Watanabe K, Handa T, Tanizawa K, Hosono Y, Taguchi Y, Noma S, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med. 2011;105:1238–47. Intriguingly, anti-ARS antibodies were found in about 7 % of 198 consecutive patients with idiopathic interstitial pneumonias, thus giving a relevant contribution to the definition of “idiopathic” interstitial lung disease.PubMedCrossRef

31.

Shamim EA, Rider LG, Pandey JP, O'Hanlon TP, Jara LJ, Samayoa EA, et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum. 2002;46:1885–93.PubMedCrossRef

32.

Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee EB, et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord. 2010;28:11–23.

33.

Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, Ikezawa Z. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol. 2011;38:973–9.PubMedCrossRef

34.

Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391–8.PubMedCrossRef

35.

Love LA, Weinberg CR, McConnaughey DR, Oddis CV, Medsger Jr TA, Reveille JD, et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 2009;60:2499–504.PubMedCrossRef

36.

Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri S, et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford). 2010;49:2370–4.CrossRef

37.

Denslow SA, Wade PA. The human Mi-2/NuRD complex and gene regulation. Oncogene. 2007;26:5433–8.PubMedCrossRef

38.

Chinoy H, Fertig N, Oddis CV, Ollier WER, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007;66:1345–9.PubMedCrossRef

39.

Muro Y, Ishikawa A, Sugiura K, Akiyama M. Clinical features of anti-TIF1-α antibodies-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies. Rheumatology (Oxford). 2012;51:1508–13.CrossRef

40.

Römisch K, Miller FW, Dobberstein B, High S. Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res Ther. 2006;8:R39.PubMedCrossRef

41.

Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology (Oxford). 2009;48:594–5.CrossRef

42.

Takada T, Hirakata M, Suwa A, Kaneko Y, Kuwana M, Ishihara T, et al. Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies. Mod Rheumatol. 2009;19:156–64.PubMedCrossRef

43.

Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 2004;50:209–15.PubMedCrossRef

44.

Liewluck T. Comment on: clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology (Oxford). 2009;48:90–1.CrossRef

45.

Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by Melanoma Differentiation-Associated Gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2009;60:2193.PubMedCrossRef

46.

• Nakashima R, Imura Y, Kabayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49:433–40. The autoantigen recognized by anti-CADM-140 antibody was identified as the interferon induced with helicase C domain protein 1 (IFIH1), also known as MDA5 protein.CrossRef

47.

• Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation- associated gene 5 antibody. Arthritis Care Res. 2012;64:1602–10. The specificity and prognostic value of anti-MDA5 antibody in Chinese DM patients is established, also demonstrating that antibody levels are helpful in predicting ILD prognosis and response to treatment.CrossRef

48.

Yoneyama M, Fujita T. Recognition of viral nucleic acids in innate immunity. Rev Mod Virol. 2010;20:4–22.CrossRef

49.

Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1713–9.CrossRef

50.

Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O’Hanlon TP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682–9.PubMedCrossRef

51.

Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura T, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford). 2007;46:25–8.CrossRef

52.

• Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O’Callaghan A, Martınez-Gomez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis. A systematic review and meta-analysis. Arthritis Rheum. 2012;64:523–32. Based on a systematic review and meta-analysis study, the authors assessed the diagnostic value of anti-p155 testing for cancer-associated myositis.PubMedCrossRef

53.

• Selva-O'Callaghan A, Trallero-Araguas E, Grau-Junyent JM, Labrador-Horrillo M. Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol. 2010;22:627–32. This interesting review highlights recent advances in the relationship between malignancy and myositis, and proposes the best approach for cancer diagnosis in myositis patients.PubMedCrossRef

54.

Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. Anti-TIF1γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Ann Rheum Dis. 2012;71:993–6.PubMedCrossRef

55.

•• Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64:513–22. In this elegant study, the immunoreactivity and clinical associations of the autoimmune response against TIF1 family proteins were extensively analyzed in a large cohort of DM patients.PubMedCrossRef

56.

Targoff IN, Trieu EP, Levy-Neto M, Prasertsuntarsai T. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-γ) in dermatomyositis (abstract). Arthritis Rheum. 2006;54:S518.CrossRef

57.

Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010;49:1726–33.CrossRef

58.

Gunawardena H, Wedderbun LR, Chinoy H, Betteridge ZE, North J, Ollier WE, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009;60:1807–14.PubMedCrossRef

59.

Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol. 2009;36:2547–51.PubMedCrossRef

60.

Takahashi K, Yoshida N, Murakami N, Kawata K, Ishizaki H, Tanaka-Okamoto M, et al. Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell. 2007;18:1701–9.PubMedCrossRef

61.

Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;71:710–3.PubMedCrossRef

62.

Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther. 2012;14:R97.PubMedCrossRef

63.

Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 2007;56:3132–7.PubMedCrossRef

64.

Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, et al. Clinical and HLA-class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK adult-onset Caucasian myositis. Ann Rheum Dis. 2009;68:1621–5.PubMedCrossRef

65.

• Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods. 2012;384:128–34. An unlabeled protein immunoprecipitation assay applied to the identification of anti-SAE antibody is described in detail.PubMedCrossRef

66.

Fujimoto M, Matsushita T, Hamaguchi Y, Kaji K, Asano Y, Ogawa F, et al. Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis. 2013;72:151–3.PubMedCrossRef

67.

Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62:2757–66.PubMedCrossRef

68.

•• Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res. 2012;64:269–72. A community-based study assessing the high specificity of anti-HMGCR antibodies for statin-associated autoimmune myopathy requiring immunoppressive therapy.CrossRef

69.

Franceschini F, Cavazzana I, Generali D, Quinzanini M, Ghirardello A, Doria A, et al. Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. J Rheumatol. 2002;29:1393–7.PubMed

70.

Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senecal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007;9:R78.PubMedCrossRef

71.

Vancsa A, Gergely L, Ponyi A, Nemeth J, Szodoray P, Danko K. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical associations: retrospective study of 169 patients. J B Spine. 2010;77:125–30.

72.

Lega JC, Cottin V, Fabien N, Thivolet-Béjui F, Cordier JF. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition? J Rheumatol. 2010;37:1000–9.PubMedCrossRef

73.

• Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard J, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum. 2012;41:890–9. The clinical relevance of anti-Ro52 antibodies in anti-Jo 1-positive patients with autoimmune myositis was elucidated. Anti-Ro52 antibodies were significantly associated with more severe interstitial lung disease, myositis and joint involvement, and poorer long-term outcome compared with anti-Jo1-positive patients without anti-Ro52 antibodies.

74.

Ghirardello A, Bendo R, Rampudda ME, Bassi N, Zampieri S, Doria A. Commercial blot assays in the diagnosis of systemic rheumatic diseases. Autoimmun Rev. 2009;8:645–9.PubMedCrossRef

75.

Rönnelid J, Barbasso Helmers S, Storfors H, Grip K, Ronnblom L, Frank-Larsson K, et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev. 2009;9:58–61.PubMedCrossRef

76.

Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56:3125–31.PubMedCrossRef

77.

• Benveniste O, Drouot L, Joven F, Charvel J, Bloch-Queyrat C, Behin A, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 2011;67:1961–71. Anti-SRP autoantibody levels reflect the degree of myolysis and response to treatment in necrotizing myopathies.CrossRef

78.

Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strenght in anti-3-hydroxy-3-methyl-glutaryl-coenzyme A-reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64:4087–93.PubMedCrossRef

79.

Casciola-Rosen L, Nagaraju K, Plots P, Wang K, Levine S, Gabrielson E, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005;201:591–601.

80.

Mammen AL, Casciola-Rosen LA, Hall JC, Christopher-Stine L, Corse AM, Rosen A. Expression of dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum. 2009;60:3784–93.PubMedCrossRef

81.

Zampieri S, Biral D, Adami N, Ghirardello A, Rampudda M, Tonello M, et al. Expression of myositis specific autoantigens during postnatal myogenesis. Neurol Res. 2008;30:145–8.PubMedCrossRef

82.

Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol. 2012;24:602–8.PubMedCrossRef

83.

• Zampieri S, Doria A, Adami N, Biral N, Vecchiato M, Savastano S, et al. Subclinical myopathy in patients affected with early stage colorectal cancer at disease onset: evidence from skeletal muscle biopsies. Neurol Res. 2010;32:20–5. Skeletal muscle from patients with recent-onset cancer show histopathologic myopathic features similar to those observed in muscle of patients with cancer-associated myositis.PubMedCrossRef

84.

Zampieri S, Valente M, Adami N, Corbianco S, Doria A, Biral D, et al. Subclinical myopathy in patients affected with early stage colorectal cancer at disease onset: No evidence of inflammatory cells infiltration in the skeletal muscle biopsies harvested during diagnostic laparoscopy. Basic Appl Myol. 2009;19:247–52.

85.

Zampieri S, Valente M, Adami N, Biral N, Ghirardello A, Rampudda M, et al. Polymyositis, dermatomyositis and malignancy: A further intriguing link. Autoimmun Rev. 2010;9:449–53.PubMedCrossRef

86.

Lundberg IE, Helmers SB. The type I interferon system in idiopathic inflammatory myopathies. Autoimmunity. 2010;43:239–43.PubMedCrossRef

87.

Eloranta M, Barbasso Helmers S, Ulfgren A-K, Rönnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007;56:3112–24.

88.

Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, et al. Activation of the endoplasmic reticulum response in autoimmune myositis. Arthritis Rheum. 2005;52:824–35.CrossRef

89.

Tarricone E, Ghirardello A, Zampieri A, Rampudda ME, Doria A, Gorza L. Cell stress-response in skeletal muscle myofibers. Ann NY Acad Sci. 2006;1069:472–6.PubMedCrossRef

90.

•• Vitadello M, Doria A, Tarricone E, Ghirardello A, Gorza L. Myofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammation. Arthritis Res Ther. 2010;12:R52. In myositis patients, an endoplasmic reticulum-stress response occurs, mainly characterized by the upregulation of Grp94 and Grp75 chaperone proteins in regenerating myofibers.PubMedCrossRef

Titel: Autoantibodies in Polymyositis and Dermatomyositis
verfasst von: Anna Ghirardello
Nicola Bassi
Lavinia Palma
Elisabetta Borella
Marta Domeneghetti
Leonardo Punzi
Andrea Doria
Publikationsdatum: 01.06.2013
Verlag: Current Science Inc.
Erschienen in: Current Rheumatology Reports / Ausgabe 6/2013
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-013-0335-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Autoantibodies in Polymyositis and Dermatomyositis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

Clinical Management of Septic Arthritis

Vaccination and Inflammatory Arthritis: Overview of Current Vaccines and Recommended Uses in Rheumatology

The Role of Resistin in Inflammatory Myopathies

Use of New Oral Anticoagulants in Antiphospholipid Syndrome

Top 10 Things to Know About Lupus Activity Measures

Understanding Developmental Mechanisms in the Context of Osteoarthritis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin